UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 181

Sortiert nach

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

Nature reviews. Drug discovery, 2017-04, Vol.16 (4), p.273-284

2017

Volltextzugriff (PDF)

Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling

Structure (London), 2016-01, Vol.24 (1), p.179-186

2016

Volltextzugriff (PDF)

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Molecular cancer therapeutics, 2016-05, Vol.15 (5), p.1132-1144

2016

Volltextzugriff (PDF)

The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer

Clinical cancer research, 2007-10, Vol.13 (20), p.5995-6000

2007

Volltextzugriff (PDF)

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Science translational medicine, 2015-03, Vol.7 (279), p.279ra40

2015

Volltextzugriff (PDF)

Disruption of XIAP-RIP2 Association Blocks NOD2-Mediated Inflammatory Signaling

Molecular cell, 2018-02, Vol.69 (4), p.551-565.e7

2018

Volltextzugriff (PDF)

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

Nature (London), 2011-03, Vol.471 (7336), p.110-114

2011

Volltextzugriff (PDF)

Structures of autoinhibited and polymerized forms of CARD9 reveal mechanisms of CARD9 and CARD11 activation

Nature communications, 2019-07, Vol.10 (1), p.3070-17, Article 3070

2019

Volltextzugriff (PDF)

A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells

Nature chemical biology, 2018-06, Vol.14 (6), p.582

2018

Volltextzugriff (PDF)

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

Journal of medicinal chemistry, 2012-05, Vol.55 (9), p.4101-4113

2012

Volltextzugriff (PDF)

IAP antagonist GDC-0917 is more potent than Debio1143 in promoting cell death, c-IAP1 degradation and tumor growth inhibition

Cell death & disease, 2022-09, Vol.13 (9), p.831-3, Article 831

2022

Volltextzugriff (PDF)

Designer Proteins to Trigger Cell Death

Cell, 2014-06, Vol.157 (7), p.1506-1508

2014

Volltextzugriff (PDF)

Navitoclax Enhances the Efficacy of Taxanes in Non―Small Cell Lung Cancer Models

Clinical cancer research, 2011-03, Vol.17 (6), p.1394-1404

2011

Volltextzugriff (PDF)

Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1)

Biochemical journal, 2009-01, Vol.417 (1), p.149-165

2009

Volltextzugriff (PDF)

Conformational dynamics control ubiquitin-deubiquitinase interactions and influence in vivo signaling

Proceedings of the National Academy of Sciences - PNAS, 2013-07, Vol.110 (28), p.11379-11384

2013

Volltextzugriff (PDF)

Characterization of ML-IAP protein stability and physiological role in vivo

Biochemical journal, 2012-11, Vol.447 (3), p.427-436

2012

Volltextzugriff (PDF)

Identification of a Novel Homotypic Interaction Motif Required for the Phosphorylation of Receptor-interacting Protein (RIP) by RIP3

The Journal of biological chemistry, 2002-03, Vol.277 (11), p.9505-9511

2002

Volltextzugriff (PDF)

Heterobifunctional Molecules Induce Dephosphorylation of Kinases–A Proof of Concept Study

Journal of medicinal chemistry, 2020-03, Vol.63 (6), p.2807-2813

2020

Volltextzugriff (PDF)

Murine Insulin Growth Factor-like (IGFL) and Human IGFL1 Proteins Are Induced in Inflammatory Skin Conditions and Bind to a Novel Tumor Necrosis Factor Receptor Family Member, IGFLR1

The Journal of biological chemistry, 2011-05, Vol.286 (21), p.18969-18981

2011

Volltextzugriff (PDF)

X Chromosome-linked Inhibitor of Apoptosis Regulates Cell Death Induction by Proapoptotic Receptor Agonists

The Journal of biological chemistry, 2009-12, Vol.284 (50), p.34553-34560

2009

Volltextzugriff (PDF)

Antagonism of c-IAP and XIAP Proteins Is Required for Efficient Induction of Cell Death by Small-Molecule IAP Antagonists

ACS chemical biology, 2009-07, Vol.4 (7), p.557-566

2009

Volltextzugriff (PDF)

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax

Cancer discovery, 2017-12, Vol.7 (12), p.1376-1393

2017

Volltextzugriff (PDF)

Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP

Biochemical journal, 2005-01, Vol.385 (Pt 1), p.11-20

2005

Volltextzugriff (PDF)

1 – 25 von 181

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(144)

Publikationsform

Sprache

Englisch
(181)
Japanisch
(30)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation

Disruption of XIAP-RIP2 Association Blocks NOD2-Mediated Inflammatory Signaling

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

Structures of autoinhibited and polymerized forms of CARD9 reveal mechanisms of CARD9 and CARD11 activation

A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

IAP antagonist GDC-0917 is more potent than Debio1143 in promoting cell death, c-IAP1 degradation and tumor growth inhibition

Designer Proteins to Trigger Cell Death

Navitoclax Enhances the Efficacy of Taxanes in Non―Small Cell Lung Cancer Models

Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1)

Conformational dynamics control ubiquitin-deubiquitinase interactions and influence in vivo signaling

Characterization of ML-IAP protein stability and physiological role in vivo

Identification of a Novel Homotypic Interaction Motif Required for the Phosphorylation of Receptor-interacting Protein (RIP) by RIP3

Heterobifunctional Molecules Induce Dephosphorylation of Kinases–A Proof of Concept Study

Murine Insulin Growth Factor-like (IGFL) and Human IGFL1 Proteins Are Induced in Inflammatory Skin Conditions and Bind to a Novel Tumor Necrosis Factor Receptor Family Member, IGFLR1

X Chromosome-linked Inhibitor of Apoptosis Regulates Cell Death Induction by Proapoptotic Receptor Agonists

Antagonism of c-IAP and XIAP Proteins Is Required for Efficient Induction of Cell Death by Small-Molecule IAP Antagonists

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax

Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP

Suchergebnisse filtern